Yarrow

Yarrow is an RTW-incubated company developing antisense oligonucleotide (ASO) therapeutics for severe, genetically defined CNS diseases.

Recent advances have enabled and derisked development of ASO therapeutics for CNS diseases. Next generation sequencing has improved diagnosis and patient pool access. Whilst fundamental understanding of CNS biology has made big strides thanks to improved sequencing, biochemistry, and imaging techniques, allowing the deciphering of molecular mechanisms that cause a disease. Furthermore, improved potency and performance through widened medicinal chemistry repertoire and better molecular understanding, as well as and increases number of tractable CNS genetic targets resulted in substantial improvements in ASO therapeutics design.

Founded
2021
Location
New York, NY
Phase
Preclinical
Tags

The need

There are 100+ genetically-defined CNS diseases tractable antisense with oligonucleotide (ASO) therapeutics. However, only 7 monogenic CNS diseases have ASOs in development or approved. Genetically defined CNS diseases provide a vast opportunity for new, innovative ASO therapeutics.

Mission

Yarrow is developing ASO therapeutics for severe, genetically defined CNS diseases. Yarrow was founded and incubated by RTW team in New York and is rooted in the firm’s longstanding expertise and commitment to solving genetic diseases and oligotherapeutics.

Next milestone

By working closely with the Yarrow team, we look to expand Yarrow’s internal R&D capabilities, in-licence additional assets into the growing pipeline and further capitalize its business and team expansion.

Pipeline

Preclinical
Phase 1
Phase 2
Phase 3
Registrational
Commercial

  • ASO TECHNOLOGY

  • Pre-clinical
  • Phase 1-3
  • Registrational
  • Commercial
EXPLORE THE NEXT COMPANY
Armo BioSciences

Speak to a member of our team